The New Era of Neuromyelitis Optica Spectrum Disorder: Advances in Diagnosis and Treatment
July 31, 2020
July 31, 2021
Scroll to the Bottom of this Information to Begin this Course
Provided by The Consortium of Multiple Sclerosis Centers and Catamount Medical Education.
This activity is supported in part by independent education grants from Alexion Pharmaceuticals and Genentech.
- Physicians — maximum of 1.25 AMA PRA Category 1 Credit(s)™
- Nurses — 1.25 Nursing Contact Hours
- Pharmacists — 1.25 Contact Hours (0.125 CEUs)
All other healthcare professionals completing this course will be issued a statement of participation.
The target learning audience for this initiative is neurologists, nurses, nurse practitioners, PAs, pharmacists, and other members of the healthcare team essential to the diagnosis and management of patients with NMOSD.
Statement of Need/Program Overview
This activity reviews evidence-based recommendations, challenges, and advances in the diagnosis and treatment of NMO spectrum disorder.
Upon completion of this activity, participants should be better able to:
- Define symptoms of NMOSD and common diseases that mimic NMOSD
- Summarize consensus diagnostic criteria for NMOSD
- Review diagnostic testing methods for NMOSD
- Employ team-based approaches to the early and accurate diagnosis of NMOSD
- Review novel treatment options for NMOSD
- Apply evidence-based approaches to personalizing treatment for patients with NMOSD
Brian G. Weinshenker, MD, FRCP(C)
Consultant, Department of Neurology
Professor of Neurology, College of Medicine
Marcelo Matiello, MD
Assistant Professor of Neurology, Harvard Medical School
Director, Massachusetts General Hospital Neurology Inpatient Services
Director, Massachusetts General Hospital Routine and Urgent Teleneurology Program
Associate Director, Neuromyelitis Optica Clinic and Research Unit
In support of improving patient care, this activity has been planned and implemented by the Consortium of Multiple Sclerosis Centers (CMSC) and Catamount Medical Education. CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The CMSC designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Credit Designation
The CMSC designates this activity for a maximum of 1.25 contact hours of continuing nursing education (0.5 in the area of pharmacology).
This knowledge-based activity, UAN JA4008165-9999-20-037-H01-P, qualifies for 1.25 contact hours (.125 CEUs) of continuing pharmacy education credit.
Upon successful completion of the activity, your CE credits will be submitted electronically to the NABP CPE Monitor service. Paper certificates are not valid. For information about CPE Monitor, visit https://nabp.pharmacy/cpe-monitor-service/
Disclosures of Conflicts of Interest
Brian G. Weinshenker, MD, FRCP(C)
Dr. Weinshenker has disclosed the following relationships:
- Royalty: RSR Ltd, Oxford University, Hospices Civil de Lyon, MVZ Labor PD Dr. Volkmann Kollegen GbR
- Receipt of Intellectual Property Rights/Patent Holder: Patent for use of NMO-IgG as diagnostic test for neuromyelitis optica spectrum disorder
- Consulting Fee: Chugai/Roche/Genentech re satralizumab clinical trial; Mitsubishi Tanabe re trial design
- Fees for Non-CME/CE Services Received Directly from a Commercial Interest or its Agent: Genentech
- Other: Chair for attack adjudication committee for Alexion and MedImmune/Viela Bio
Marcelo Matiello, MD
Dr. Matiello has disclosed the following relationships:
- Consulting Fee: Vielabio
Accreditor and Planning Committee Disclosures:
June Halper, MSN, APN-C, MSCN, FAAN, has declared that she has no relevant financial relationships to disclose.
All other planners, reviewers, staff, or other members of the Continuing Professional Education Committee at the Consortium of Multiple Sclerosis Centers who control content have disclosed no relevant financial relationships.
Laurie Scudder, DNP, NP, has served as Nurse Planner for this activity. She has declared that she has no relevant financial relationships to disclose.
Publishing Staff Disclosures:
The planners, reviewers, editors, staff, CME committee, or other members at Catamount Medical Education who control content have disclosed no relevant financial relationships.
Instructions for Participation and Credit
There are no fees for participating and receiving CME/CE credit for this enduring activity. To receive CME/CE credit participants must:
- Read the CME/CE information and faculty disclosures
- Complete the pre-test
- Participate in the online activity
- Complete the post-test with a score of 65% or higher; you may take the post-test as many times as you require to pass
- Complete the evaluation
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
CMSC and Catamount Medical Education require CME/CE faculty (speakers) to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
During this presentation, Dr. Weinshenker may reference satralizumab, and other immunosuppressant medications to treat neuromyelitis optica spectrum disorder. Dr. Matiello may reference azathioprine, prednisone, mycophenolate mofetil, Methotrexate, mitoxantrone, and plasmapheresis.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
For questions about this activity, please contact Catamount Medical Education at: email@example.com.
The Consortium of Multiple Sclerosis Centers and Catamount Medical Education, LLC, respect your privacy. All personal information that is provided to Catamount Medical Education, LLC, is protected and will not be sold to a third party for commercial purposes. All personally identifiable information contained in the Catamount Medical Education, LLC, registration databases is treated as confidential and will be used only for the purposes stated in this policy, except where required by law. Catamount Medical Education, LLC, maintains user databases that contain mailing and user profile information as well as a record of the CME activities viewed and the post-test and evaluation results for CME/CE credit. This information is provided to activity collaborators for the purposes of CME/CE recordkeeping. By participating in this activity, you agree that Catamount Medical Education, LLC, has full permission to provide this information.
Catamount Medical Education, LLC, safeguards against the loss, misuse, or alteration of information that we have collected in this activity.